These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 29364586)

  • 21. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
    Lorenz M; Evers A; Wagner M
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
    Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
    Ng VWW; Gerard G; Koh JJK; Loke KY; Lee YS; Ng NBH
    Clin Obes; 2024 Jun; 14(3):e12642. PubMed ID: 38273176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Shaughnessy AF
    Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2018 Jul; 52(7):632-638. PubMed ID: 29424239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two new GLP-1 receptor agonists for diabetes.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
    Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
    Ross SA; Ballantine J
    Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
    Boyle JG; Livingstone R; Petrie JR
    Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
    Diabetes Obes Metab; 2024 Sep; 26(9):3906-3913. PubMed ID: 38934217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
    Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
    Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.
    Rodbard HW
    Diabetes Technol Ther; 2018 Jun; 20(S2):S233-S241. PubMed ID: 29870275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.